Drugs / Abobotulinum Toxin Type A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04589364 | May 2024 → Jun 2026 overdue | facial spasm | Department of Medical Services Ministry of Public Health of Thailand | Not yet recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-04-06 | Galderma R&D | Galderma´s Azzalure and Dysport® celebrate a decade of treatment of the glabellar lines galderma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Abobotulinum Toxin Type A | “Abobotulinum Toxin Type A (Dysport) dose was investigated:” NCT04589364 ↗ |
| Known as | Dysport | “Abobotulinum Toxin Type A (Dysport) dose was investigated:” NCT04589364 ↗ |
| Route | Intramuscular | “intramuscular injection of 100 unit of Abobotulinum Toxin Type A” NCT04589364 ↗ |